Eagle Pharmaceuticals Inc (EGRX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE, NJ 07677

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company develops and distributes injectable products, primarily in the critical care and oncology areas.

Data as of 2020-08-01
Market Cap634.853 Million Shares Outstanding13.685 Million Avg 30-day Volume171.514 Thousand
P/E Ratio280.8 Dividend Yield EPS0.17
Price/Sales4.688 Price cash flow ratio20.2 Price free cash flow ratio67.6
Book Value13.29 Price to Tangible Book5.14 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.061259
BETA0.946325 52-week High/Low64.94 / 33.8 Stddev0.164503
View SEC Filings from EGRX instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 1 (0.07%)
13F Filers holding this stock: 164 48 (3.14%)
Aggregate 13F shares on 03/31/2020: 13.007 Million 5.139 Million
Aggregate 13F shares on 12/31/2019: 13.35 Million 5.558 Million
Percent change: -2.57% -7.54%
Funds creating new positions: 18 4
Funds Adding to an existing position: 59 17
Funds closing out their position: 24 8
Funds reducing their position: 59 20
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding EGRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EGRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SIMPSON JENNIFER K. PRESIDENT AND CEO

  • Officer
  • Director
0 2020-07-15 3

HUDSON EXECUTIVE CAPITAL LP

HEC MANAGEMENT GP LLC

BRAUNSTEIN DOUGLAS L

  • Director
  • 10% Owner
11,036,174 2020-06-30 4

TARRIFF SCOTT CEO

  • Officer
  • Director
  • 10% Owner
1,550,954 2020-01-23 2

HEPNER ADRIAN EVP AND CHIEF MEDICAL OFFICER

  • Officer
48,784 2020-01-23 2

PERNOCK DAVID PRES. & CHIEF COMM. OFFICER

  • Officer
49,811 2020-01-23 2

MEYERS PETE A. CHIEF FINANCIAL OFFICER

  • Officer
43,615 2020-01-23 2

RATOFF STEVEN B

  • Director
0 2020-01-05 1

GRAVES MICHAEL

  • Director
0 2020-01-05 1

GLENNING ROBERT

  • Director
0 2020-01-05 1

EDLIN RICHARD A.

  • Director
0 2020-01-05 1

BRAUNSTEIN DOUGLAS L

  • Director
0 2019-10-29 3

FLAUM SANDER A

  • Director
13,510 2019-03-05 0

KRILL STEVEN L. EVP & CHIEF SCIENTIFIC OFFICER

  • Officer
3,000 2018-01-07 0

PROQUEST INVESTMENTS IV, L.P.

PROQUEST FINANCIAL LLC

PROQUEST ASSOCIATES IV LLC

MOORIN JAY

SCHREIBER ALAIN

  • 10% Owner
No longer subject to file 2017-05-15 0

RIGGS DAVID E CHIEF FINANCIAL OFFICER

  • Officer
0 2017-01-04 0

PROQUEST MANAGEMENT LLC

PROQUEST INVESTMENTS IV, L.P.

PROQUEST ASSOCIATES IV LLC

MOORIN JAY

SCHREIBER ALAIN

  • Director
  • 10% Owner
4,780,188 2016-05-20 0

PROQUEST FINANCIAL LLC

  • 10% Owner
4,780,188 2016-05-20 0

MOORIN JAY

  • Director
642,858 2016-01-12 0

SCHREIBER ALAIN

  • Director
0 2016-01-04 0

BRUINENBERG PAUL CHIEF MEDICAL OFFICER

  • Officer
0 2014-08-26 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments